Case study

The benefits of a joint audit approach at Pall Corporation

The context

Site audits are an essential but increasing burden for manufacturers and customers and brought into sharp focus during Covid-19 when local and international lockdowns meant that traveling to sites was near impossible. What was needed was a new way of performing audits that was more efficient, did not require a visit by every customer, and allowed audit reports to be shared by a range of customers.

biophorum resized biophorum resized pall corp 49

This is why BioPhorum and Rx-360 collaborated to assess whether a Joint Audit Program model was appropriate for manufacturers, with a specific spotlight on auditing single-use systems. The approach was deemed a success and further details can be found in BioPhorum’s Pilot Report and the Single-Use Audit Guide.

An Rx-360 Joint Audit Program® approach can offer audits of greater depth while reducing the audit burden as customers can buy a license to use the joint audit report. To find out how it is working in practice, we spoke to two subject matter experts at Pall Corporation about the benefits of a Joint Audit Program and how they have used it in their business.

What was the issue you needed to address?

“Although we have ISO certifications in place, our pharmaceutical customers still wanted to visit our sites to perform audits,” said Mark van Kollenburg, Global Quality Compliance Manager at Pall Corporation. “But we have seen an exponential growth in individual audits over the last few years and now have more than 300 annual audits when all our biotech sites are included. This obviously places a great demand on our resources and we wanted to find a better solution, especially when Covid-19 prevented customers from traveling.”

He explained that the main reason Pall wanted to use the Rx-360 Joint Audit Program® was to try to reduce the number of individual customer audits and for them to share a joint audit report. “We could see that around 80% of audits were comparable and asked similar questions. This independent joint auditing process gives our customers confidence that professional auditors perform the visits leading to an independent report that they can use. As a result, we have seen a significant uptake from customers and are over 100 licenses being bought, mostly in 2022.”

The exponential growth in using single-use systems by Pall’s pharmaceutical customers was also a driver. Van Kollenburg added, “We had extra qualification audits and significant growth in our sites and their onsite activities, leading to more customer notifications of our extended activities. This all led to more customers wanting to visit our sites to qualify our increased activities.”

The increased need for our products and customers’ travel restrictions meant everyone was more open to accepting alternative solutions.

Mark van Kollenburg, Global Quality Compliance Manager at Pall Corporation

How have you implemented the solution?

“We have implemented the Joint Audit Program solution across all of our biotech sites for external facing audits, mostly focusing on consumable manufacturing sites,” said van Kollenburg.

Van Kollenburg explained that Pall’s equipment manufacturing sites are less frequently visited by customers because Pall supplies equipment with site acceptance tests directly to them, so there is a more one-on-one situation. “Whereas consumable products are supplied off-the-shelf or from our sites to multiple customers. The needs of the supplier or customer base are much greater for consumable parts, so the need for an audit is also much more significant. At the same time, we still do our own internal audits as originally planned.”

What are the benefits of the Rx-360 Joint Audit Program®?

“The growth in the number of requested audits means that we still have the same number per site, but by using the Rx-360 Joint Audit Program®, we can handle an extra 25% of audits without additional people,” said Hélène Pora – Vice President, Technical Communication and Regulatory Strategy at Pall Corporation. She added that this means Pall can allocate resources to other activities.

“The growth in our business and the number of change notifications to customers allows us to get their quick approval based on the joint audit report,” added van Kollenburg. “They may still come to perform their own audit later, but the benefit to us is that we can accelerate the expansion and approval of our activities.”

An additional benefit is that the reports are typically more detailed and provide more depth than the usual customer audit.

Did you have any issues and how did you overcome them?

“Conversations with senior management and legal departments about the benefits of the process took a while to work through,” said Pora, “and confidentiality of the information in the report was an important topic that we discussed. But it helped that we had plans to expand capacity and we wanted to drive the acceptance of additional lines and sites. Once we had a site ready to go, we didn’t want to wait one or two years until people started doing their audits. We found the Rx-360 Joint Audit Program® was a way to get quicker acceptance of our sites.”

She added, “Obviously, there is only a certain number of audits we can handle, so without the Joint Audit Program, the queue of customer audits would just get longer. For example, we have been booking visits for 2023 for some time.”

Do you have any pointers for the future?

“One thing to note is that once you’ve done an audit, you need to have a full maintenance program in place,” said Pora. “That is something we must plan for as we get additional lines at our manufacturing sites. Also, the audits will ‘age’, so we must repeat them to ensure they are still appropriate.”

Van Kollenburg said Pall usually has to pay for the audit approach, while the customer wanting the report must buy a license to use it. “The Rx-360 Joint Audit Program® however, allows us to request an audit of our facility, or we can go to Rx-360 and say that we want a site to be audited and they will then look for co-sponsors. Most of the time, they find sufficient co-sponsors, who are also our customers, and their members.”

In summary, the Rx-360 Joint Audit Program®has given more pharmaceutical companies faster access to audit reports, and enabled them to expand their capacity for receiving audits at their manufacturing sites, without increasing resources.

Note: Rx-360 and Joint Audit Program are trademarks of Rx-360 International Pharmaceutical Supply Chain Consortium a non-profit corporation.

Cell & Gene Therapy

Maximizing the impact of the many advanced therapies under development requires that the industry comes together to improve understanding of how to develop, control and manufacture these life changing therapies.

We connect strategic thinkers in drug development and contract manufacturing organizations with the aim of ensuring harmonization and alignment around issues such as potency assays, phase-appropriate guidance for critical quality attributes, operator safety, regulatory guidelines, and C&GT-specific validation issues, as well as working toward resolving the current challenges to commercializing C&GT products. Discover more and learn about the outputs here.

Development Group

The ever-increasing need to reduce product development lead times and the opportunities to exploit innovative technologies in development are two key industry themes that remain at the forefront of our work. The Phorum successfully connects process development organizations and provides a space where subject matter experts can work on issues such as quality by design and process characterization, cell line technologies, and molecule selection. Read some of the outputs and discover how you could benefit by getting involved.

Drug Substance

Accelerating improvement, exploiting opportunities offered by innovation, and identifying best practice approaches across all aspects of the manufacturing process – these are the essential objectives

Data and digital capabilities are at the core of many of these industry challenges. Work in BioPhorum Drug Substance is informed by BioPhorum Technology Strategy, which has summarized our industry’s market drivers and trends. Capacity, flexibility, sustainability and pace all feature as requirements to succeed in a rapidly changing environment.

Find out more about what our members are currently discussing and learn about some of the successful implementations of our output.

Fill Finish

Quality and demonstrating compliance are two priorities of BioPhorum Fill Finish. Representatives of the world’s top sterile filling operations come together to develop solutions to some of the most intractable technical and regulatory challenges.To address these challenges in drug product aseptic filling (‘fill’) and secondary packaging (‘finish’) operations, our community of industry experts is working relentlessly to continually improve the pharmaceutical quality system (PQS). Together they continue to strive towards developing and implementing safe, predictable, lean, and agile processes in drug product operations. Find out more about the Phorum output here. 

Information Technology

IT and digital advances are crucial in responding to the pharmaceutical industry’s challenges around speed, cost, quality, flexibility, and sustainability. Unlocking and realizing the value in the industry’s IT opportunities is the core mission of the IT Phorum. 

The digital manufacturing facility of the future needs to consider technology advances alongside organizational perspectives while maintaining foundational security requirements. All elements must be considered in the long term to deliver systemic change toward the digital factory vision. Our members collaborate in a format that stimulates and supports industry innovation and implementation. 


BioPhorum Regulatory CMC is affording professionals the opportunity to shape their own collaboration program focused on challenges and opportunities across strategy, science, operations, submissions and compliance. Following a discovery program of work with Heads of Regulatory CMC, in which we identified some key topics of collaboration, we are giving you the opportunity to participate and help us to shape the final collaboration program. This will focus on, filing and review, interactions with Health Authorities, and harmonization. Our mission is not just to discuss, but to deliver applicable outputs and publications that will have an impact – learn more about how you can get involved.

Supply Chain to Patient

The pharmaceutical outbound supply chain was built on a blockbuster model and doesn’t fit the needs of the changing pipeline and new modalities currently being developed. The geopolitical challenges of recent years have shown that the outbound supply chain needs to evolve to become more agile, and resilient, and address a more expectant end-user bying on patient-centricity. Industry collaboration can accelerate improvements and transform performance in a way not possible when working independently. This Phorum is founded on the belief that learning from each other and challenging current thinking to re-imagine the supply chain can reduce costs and increase efficiency.

Supply Partner

BioPhorum SP members want the inbound supply chain for the biomanufacturing industry to be recognized as one of the best-understood and managed global supply chains. They intend to be not only a trusted advisory group but also the engine that drives change for the industry. Working together, we aim to achieve supply chain transformation that provides:

  • an enhanced robustness and resilience
  • accelerated capability and capacity to effect technology adoption
  • reduced cost of quality, and
  • industry-wide alignment on operational implementation

There’s an extensive list of Phorum successes and tangible benefits that have been delivered to define industry best practise.


The BioPhorum Sustainability program is jointly designed, governed, and delivered by a membership drawn from licence holders, contract manufacturers, major suppliers and niche suppliers. This dynamic partnership means that we can quickly focus on the areas that have the greatest industry impact, and we can leverage learning from each other and other sectors – the chemical industry and the built environment for example.

BioPhorum’s unique ability to build a strong coalition for change for an entire industry is now being applied to the greatest challenge of our generation. Driven by evident industry needs, Phorum members are working to develop agreed industry benchmarks, establish the ROI of sustainability investments and to increase the efficacy of implementation of members’ sustainability strategies.

Technology Strategy

With a mission to define strategies to accelerate technology transformation and support the adoption of innovative technologies, BioPhorum Technology Strategy evolved from BioPhorum Technology Roadmapping, strives to realize the technology roadmap vision 2.0.

This is being achieved through a multi-stakeholder team of member companies with collective capability and influence who are committed to driving forth industry goals associated with: Speed to market, Quality, Value, Agility and On-Demand Supply and Sustainability.

Building on industry feedback to standardize plasmid release specifications

Plasmids release specifications are critical to the manufacture of many cell and gene therapy (CGT) products, but current regulatory... read more

How to predict, optimize and analyze high-concentration biologic therapeutic formulations

Developing high-dose biologic drugs for subcutaneous injection often requires high-concentration formulations. It also needs to optimize... read more

A media fingerprinting toolbox that comes with a host of benefits

Cell culture media raw materials can contain many chemical substances, each with its own properties. While simple substances can be... read more

Why 100% visual inspection does not mean 100% defect detection

There is a common misunderstanding that 100% visual inspection (VI) of biopharmaceutical products should mean 100% detection of defects.... read more

How to bridge the data integration gap between sponsors and contract organizations

Bringing BioPhorum’s unique perspective to continuous manufacturing in biologics

Continuous manufacturing (CM) has been a goal for the pharmaceutical industry for several years. While small molecule drug substances and... read more

Supply Chain to Patient has launched!

Have your outbound supply chain costs increased? Do you want to leverage data and digital technologies more effectively to reduce... read more

Electronic data exchange – the foundation for an efficient, resilient inbound supply chain

The COVID-19 pandemic, geopolitical unrest, and military action across the world have fundamentally disrupted the assumption and practice... read more

How are you improving your environmental sustainability performance?

Climate change and global warming resulting from greenhouse gas emissions are widely recognized as the biggest threats to global health.... read more

Adding value for analytical instrument partners

Analytical instrument vendors have been integral to developing and publishing our technology roadmaps and developing product... read more

Introducing MediPhorum

The medical technology (MedTech) industry is a critical and complex sector. As highlighted during the Covid-19 pandemic, the MedTech industry provides a wide array of products and technologies that are vital to the safe and effective provision of care to many. Also, as seen over recent years, there is often the requirement for flexibility in supply, rapid development, and the introduction of new products to keep pace with global public health demands.

Advanced Wound Care and Wound Management

Advanced wound care (AWC) is the medical treatment for wounds that have not healed properly using conventional wound care products such as gauze, bandages, plasters, and wadding.

AWC involves treating chronic or complex wounds using products that are not as easily obtained over the counter. AWC can be divided into three main categories: wound healing, infection prevention, and restoration.

Drug Delivery

Drug delivery products are therapeutic and diagnostic products combining drugs, devices, and/or biological products, which enable safer and more efficient treatment due to careful and precise drug targeting, local administration, and tailored treatment.

Introducing the new MediPhorum

MediPhorum by BioPhorum has been launched to bring together senior business leaders and subject matter experts across multiple MedTech... read more

Introducing the new MediPhorum

MediPhorum by BioPhorum has been launched to bring together senior business leaders and subject matter experts across multiple MedTech... read more

Introducing the new MediPhorum

MediPhorum by BioPhorum has been launched to bring together senior business leaders and subject matter experts across multiple MedTech... read more
BioPhorum Deliverables Report
BioPhorum brings you the latest Deliverables Report, an informative and inspiring consolidation of the benchmarks, position papers, guidance documents, assessment tools, industry user requirements, study results, and roadmaps produced in the last twelve months.
BioPhorum Downloads
Access a variety of free tools and papers and other resources designed to provide you with up-to-date information and insights to help you make informed decisions and maximize your success. Access our resources today and start making improving and streamlining your business processes.
Case Studies
Welcome to the BioPhorum case studies page, where you can learn how our clients have used our service to discover innovative solutions and save money. Here you can read real-life stories of how various organizations have used our unique data-driven approach to streamline their processes and make the most of their resources. Whether you're looking for inspiration or want to learn more about the potential benefits of our service, you'll find it here.
Webinars and podcasts
Welcome to BioPhorum Connect, the podcast series that keeps you up to date with the latest news and trends in the biopharmaceutical industry. From experienced professionals to thought leaders, this podcast brings you the insights and perspectives of experts from around the world. We'll discuss all aspects of the biopharmaceutical industry, from digitization and knowledge management to raw materials, supply chain, sustainability and more. So, join us on our journey as we explore the world of biopharmaceuticals and learn from the perspectives of those at the forefront of the industry.